Clinical Report: Reflections from ASRS

Overview

The ASRS annual meeting highlighted advancements in ocular oncology, pediatric retina, and uveitis treatments. Key discussions included the role of AI in ROP care and the evolving landscape of uveal melanoma management.

Background

The American Society of Retina Specialists (ASRS) annual meeting serves as a critical platform for retina specialists to exchange knowledge on emerging treatments and clinical practices. With the increasing complexity of retinal disorders, staying updated on the latest advancements is essential for optimizing patient outcomes. This year's conference emphasized the importance of timely diagnosis and innovative therapies in ocular oncology and uveitis.

Data Highlights

No specific numerical data was provided in the source material.

Key Findings

• Discussion on appropriate radiation doses for treating uveal melanoma.
• Importance of timely diagnosis and management of vasoproliferative tumors to prevent vision loss.
• Advancements in AI for standardizing ROP diagnosis and monitoring progression.
• Review of IL-6 inhibitors under investigation for noninfectious uveitis.
• Challenges and efficacy of the port delivery system (PDS) for ranibizumab in retinal treatments.

Clinical Implications

Retina specialists should consider integrating AI tools to enhance ROP care and improve diagnostic accuracy. Additionally, understanding the evolving treatment landscape for uveal melanoma and uveitis can guide clinical decision-making and improve patient management.

Conclusion

The ASRS meeting underscored the dynamic nature of retinal care, highlighting the need for continuous education and adaptation to new therapies. Collaboration and knowledge sharing within the retina community are vital for advancing patient care.

References

1. Diana V. Do, MD, Retinal Physician, 2025 -- Reflections from ASRS
2. Geoffrey G. Emerson, MD, PhD, Retinal Physician, 2025 -- Incoming ASRS President Shares Vision for Future
3. Ophthalmology Management, 2025 -- Refining Our Approaches to Cataract and Refractive Surgery
4. Ophthalmology Management, 2025 -- Eye On OOSS: Strategic ASC Development in Focus
5. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28 - PubMed
6. International Classification of Retinopathy of Prematurity, 3rd edition - PMC
7. Adalimumab approved to treat noninfectious uveitis | MDedge
8. ophthalmology management — A Transformative Period
9. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28 - PubMed
10. International Classification of Retinopathy of Prematurity, 3rd edition - PMC
11. Adalimumab approved to treat noninfectious uveitis | MDedge